Johnson & Johnson International, EDB to Foster Innovation within Singapore's Life Sciences Sector



A partnership between Johnson & Johnson International (Singapore) Pte. Ltd. and the Singapore Economic Development Board (EDB) has commenced in an effort to foster innovation within Singapore's life sciences sector.

This groundbreaking partnership will take advantage of Johnson & Johnson Innovation's JLABS services and innovation resources in an effort to increase the production of innovation in the area.

As part of this partnership, JLABS will assist early-stage businesses having a presence in Singapore in order to hasten the development of novel medicines, medical technologies, and healthcare solutions.

To encourage employment and commercialization prospects for early-stage enterprises, JLABS will also work with regional incubators and other strategic partners in the ecosystem on investment and talent development programs.

With the goal of addressing urgent unmet medical and healthcare needs, Johnson & Johnson is continuing its commitment to support and advance the best science and technology in the Asia Pacific area as seen by our partnership with EDB. It expands on the achievements of JLABS' no-strings-attached strategy, its more than ten years of expertise, and its standing as the biggest global network of life science entrepreneurs, investors, and corporate partners.

“At Johnson & Johnson Innovation, we source and cultivate the world’s most promising, early- stage healthcare innovation wherever it originates,” said William N. Hait, M.D., Ph.D., Executive Vice President, Chief External Innovation and Medical Officer, Johnson & Johnson. 


“We are thrilled to partner with EDB to advance the thriving life sciences community in Singapore and help unleash the potential of healthcare innovation in the Asia Pacific region for the rest of the world.”

“The needs of the next generation of global innovators, potential partners, and early-stage companies are changing rapidly, and Johnson & Johnson is committed to pioneering new approaches to address them, like this significant collaboration with EDB,” said Melinda Richter, Global Head of Johnson & Johnson Innovation – JLABS. “This type of collaboration exemplifies our pivotal role as an innovation, talent, economic and venture developer with a mission to empower our partners with the knowledge, experience, networks and practical frameworks they need to make an impact for patients.”

Before the end of the year, Johnson & Johnson Innovation - JLABS and EDB will co-host a symposium in Singapore, with subsequent announcements coming from this new partnership.

Current Issue